國立虎尾科技大學 |

Lipid Signaling in Human Diseases

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Lipid Signaling in Human Diseases/ edited by Julian Gomez-Cambronero, Michael A. Frohman.
其他作者:	Gomez-Cambronero, Julian.
面頁冊數:	XIV, 336 p. 50 illus., 30 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Pharmacology. -
電子資源:	https://doi.org/10.1007/978-3-030-33668-4
ISBN:	9783030336684

Lipid Signaling in Human Diseases
Lipid Signaling in Human Diseases[electronic resource] /edited by Julian Gomez-Cambronero, Michael A. Frohman. - 1st ed. 2020. - XIV, 336 p. 50 illus., 30 illus. in color.online resource. - Handbook of Experimental Pharmacology,2590171-2004 ;. - Handbook of Experimental Pharmacology,224.

Part 1. New Roles for Sphingolipid Signaling and Cell Function -- 1. Role of Sphingosine Kinase 1 and Sphingosine-1-Phosphate Axis in Hepatocellular Carcinoma -- 2. Exploring the Therapeutic Landscape of Sphingomyelinases -- 3. Sphingosine kinases as druggable targets -- Part 2. Phospholipase D and Mitogen Phosphatidic Acid in Human Disease -- 4. Prospects for PLD inhibition in cancer and thrombotic disease -- 5. Phospholipase D and the Mitogen Phosphatidic Acid in Human Disease: Inhibitors of PLD at the Crossroads of Phospholipid Biology and Cancer -- 6. Role of Phospholipase D-Derived Phosphatidic Acid in Regulated Exocytosis and Neurological Disease -- Part 3. Lipid Kinases and Novel Regulatory Pathways -- 7. Diacylglycerol Kinase Malfunction in Human Disease and the Search for Specific Inhibitors -- 8. Functions of Nuclear Polyphosphoinositides -- Part 4. Bioactive Lipids in Health and Disease -- 9. Platelet-Activating Factor as an Effector for Environmental Stressors -- 10. Phospholipase D and Choline Metabolism -- Part 5- Lipids and Membrane Microdomains -- 11. Regulation of Inositol Biosynthesis: Balancing Health and Pathophysiology -- 12. Lipids and Membrane Microdomains: The Glycerolipid and Alkylphosphocholine Class of Cancer Chemotherapeutic Drugs -- Part 6. Nuclear Trafficking of Lipids -- 13. Inositide-Dependent Nuclear Signalling in Health and Disease -- 14. Lipids in Exosome Biology.

Lipids are an integral part of cell membrane architecture, are intermediaries in cell metabolism, and are involved in transmitting cell signals from hormones, growth factors and nutrients. A number of lipases and phospholipases, lipid kinases, lipid phosphatases, sphingosine kinases, and their reaction products have been implicated in fundamental cellular processes including cell proliferation, division and migration. These enzymes and their products underlie the molecular mechanisms of numerous human diseases, in particular metabolic disease (diabetes), cancer, neurodegenerative disease and cardiovascular disease. Over the last decade, studies have advanced to the point that a number of inhibitors for these enzymes have been developed to attempt to ameliorate these conditions; some of the inhibitors are currently in human clinical trial. The need for this book is to review the current status of this field and the prospect for the inhibitors to be clinically important. .

ISBN: 9783030336684

Standard No.: 10.1007/978-3-030-33668-4doiSubjects--Topical Terms:

583819
Pharmacology.

LC Class. No.: RM1-950

Dewey Class. No.: 615

Lipid Signaling in Human Diseases
LDR:03855nam a22004095i 4500 001 1019751
003 DE-He213
005 20200630210608.0
007 cr nn 008mamaa
008 210318s2020 gw | s |||| 0|eng d
020 $a 9783030336684 $9 978-3-030-33668-4
024 7 $a 10.1007/978-3-030-33668-4 $2 doi
035 $a 978-3-030-33668-4
050 4 $a RM1-950
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 615 $2 23
245 1 0 $a Lipid Signaling in Human Diseases $h [electronic resource] / $c edited by Julian Gomez-Cambronero, Michael A. Frohman.
250 $a 1st ed. 2020.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a XIV, 336 p. 50 illus., 30 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Handbook of Experimental Pharmacology, $x 0171-2004 ; $v 259
505 0 $a Part 1. New Roles for Sphingolipid Signaling and Cell Function -- 1. Role of Sphingosine Kinase 1 and Sphingosine-1-Phosphate Axis in Hepatocellular Carcinoma -- 2. Exploring the Therapeutic Landscape of Sphingomyelinases -- 3. Sphingosine kinases as druggable targets -- Part 2. Phospholipase D and Mitogen Phosphatidic Acid in Human Disease -- 4. Prospects for PLD inhibition in cancer and thrombotic disease -- 5. Phospholipase D and the Mitogen Phosphatidic Acid in Human Disease: Inhibitors of PLD at the Crossroads of Phospholipid Biology and Cancer -- 6. Role of Phospholipase D-Derived Phosphatidic Acid in Regulated Exocytosis and Neurological Disease -- Part 3. Lipid Kinases and Novel Regulatory Pathways -- 7. Diacylglycerol Kinase Malfunction in Human Disease and the Search for Specific Inhibitors -- 8. Functions of Nuclear Polyphosphoinositides -- Part 4. Bioactive Lipids in Health and Disease -- 9. Platelet-Activating Factor as an Effector for Environmental Stressors -- 10. Phospholipase D and Choline Metabolism -- Part 5- Lipids and Membrane Microdomains -- 11. Regulation of Inositol Biosynthesis: Balancing Health and Pathophysiology -- 12. Lipids and Membrane Microdomains: The Glycerolipid and Alkylphosphocholine Class of Cancer Chemotherapeutic Drugs -- Part 6. Nuclear Trafficking of Lipids -- 13. Inositide-Dependent Nuclear Signalling in Health and Disease -- 14. Lipids in Exosome Biology.
520 $a Lipids are an integral part of cell membrane architecture, are intermediaries in cell metabolism, and are involved in transmitting cell signals from hormones, growth factors and nutrients. A number of lipases and phospholipases, lipid kinases, lipid phosphatases, sphingosine kinases, and their reaction products have been implicated in fundamental cellular processes including cell proliferation, division and migration. These enzymes and their products underlie the molecular mechanisms of numerous human diseases, in particular metabolic disease (diabetes), cancer, neurodegenerative disease and cardiovascular disease. Over the last decade, studies have advanced to the point that a number of inhibitors for these enzymes have been developed to attempt to ameliorate these conditions; some of the inhibitors are currently in human clinical trial. The need for this book is to review the current status of this field and the prospect for the inhibitors to be clinically important. .
650 0 $a Pharmacology. $3 583819
650 0 $a Cancer research. $3 1253664
650 0 $a Medical biochemistry. $3 1254555
650 1 4 $a Pharmacology/Toxicology. $3 593882
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Medical Biochemistry. $3 668897
700 1 $a Gomez-Cambronero, Julian. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1315078
700 1 $a Frohman, Michael A. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1315079
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030336677
776 0 8 $i Printed edition: $z 9783030336691
776 0 8 $i Printed edition: $z 9783030336707
830 0 $a Handbook of Experimental Pharmacology, $x 0171-2004 ; $v 224 $3 1254015
856 4 0 $u https://doi.org/10.1007/978-3-030-33668-4
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)